Indications |
Oral Angina pectoris, Meniere's disease Adult: As conventional tab: 40-60 mg daily in divided doses. |
Contraindications |
Hypersensitivity. Pregnancy and lactation. |
Adverse Reactions |
GI disturbances, vomiting, nausea. |
Mechanism of Actions |
Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance. Absorption: Rapidly absorbed. Peak plasma concentration: within 2 hr (conventional tab); 5 hr (modified release). Excretion: Via urine, mainly as unchanged drug. Half life: 6 hr (conventional); 7 hr (modified release). |
Administration |
Should be taken with food. |
Storage Conditions |
Oral: Store below 30°C. |
ATC Classification |
C01EB15 - trimetazidine ; Belongs to the class of other cardiac preparations. |
Storage |
Oral: Store below 30°C. |
Available As |
|
Trimetazidine
Post Review about Trimetazidine Click here to cancel reply.
Trimetazidine Containing Brands
Trimetazidine is used in following diseases
Drug - Drug Interactions of Trimetazidine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.